rVSV-ZEBOV
- Generic Name
- rVSV-ZEBOV
Uganda Launches Groundbreaking First-Ever Ebola Sudan Vaccine Trial with WHO Support
• Uganda's Ministry of Health and WHO have initiated the world's first randomized vaccine trial for Ebola Sudan virus, launching in record time just four days after outbreak confirmation.
• The trial evaluates a recombinant VSV vaccine candidate, addressing the critical absence of licensed vaccines for Ebola Sudan strain, with support from global health organizations and research institutions.
• Using a ring vaccination strategy, the trial begins with 40 contacts of the first confirmed case, implementing lessons learned from Uganda's 2022 Ebola Sudan outbreak.
Ebola Vaccine Ervebo Transforms Fight Against Deadly Virus
• The rVSV-ZEBOV Ebola vaccine, known as Ervebo, has demonstrated near-perfect efficacy in clinical trials, offering hope in combating the Zaire Ebola virus strain.
• Sierra Leone is initiating a nationwide campaign targeting 20,000 frontline workers with the Ervebo vaccine to enhance preparedness for future outbreaks.
• Ervebo, a single-dose vaccine developed by Merck, utilizes a modified virus to stimulate antibody production, providing over 95% protection against the Zaire Ebola virus.
• Challenges remain in ensuring equitable access, addressing vaccine hesitancy, and establishing local vaccine manufacturing in Africa for sustainable control.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath